1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Chen Xiaoping: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab - HCC | Phase 2 | Recruiting | Chen Xiaoping | 160 | 2024-06-01 | 2025-05-01 |
Carcinoma, Hepatocellular (1) · Recurrence (1)
Hepatectomy (1) · lenvatinib (1) · tislelizumab (1)
China (1)